HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patiromer plus spironolactone in resistant hypertension and CKD.

Abstract
Review of: Agarwal R, Rossignal P, Romero A, et al Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540-1550.
Authors
JournalDrug and therapeutics bulletin (Drug Ther Bull) Vol. 58 Issue 8 Pg. 119 (Aug 2020) ISSN: 1755-5248 [Electronic] England
PMID32447279 (Publication Type: Journal Article)
Copyright© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: